Skip to Content
Morningstar

DexCom Inc DXCM

Morningstar Rating
Unlock
Stock XNAS Rating as of
Today’s Losers
$124.34 −13.67 (9.91%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Dexcom Earnings: Firm Poised for Strong Growth Thanks to Pools of New Patients

Debbie Wang

No-moat Dexcom posted first-quarter results that are consistent with our full-year expectations, and we're leaving our $105 fair value estimate unchanged. Quarterly sales in the US and international markets rose 24% year over year—a fast start that led to management raising the bottom end of its revenue outlook. However, our projection for $4.34 billion of full-year sales remains at the high end of management's expectations. During the first quarter, Dexcom made further progress on key initiatives that we think can support the long-term growth of this firm.

Read Full Report

Price vs Fair Value

View History
DXCM is trading at a 25% premium.
Price
$131.52
Fair Value
$485.00
Uncertainty
High
1-Star Price
$196.28
5-Star Price
$77.00
Economic Moat
Kpz
Capital Allocation
Xncgmzjyq

Bulls Say, Bears Say

Bulls

Dexcom's next-gen G7 product should be significantly less expensive, offer a thinner profile, and faster warm-up time than G6.

Bears

Considering Dexcom's sensors are already the most accurate, there's less opportunity for significant improvements on that dimension, compared with key competitors.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DXCM is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$138.01
Day Range
$124.08–138.81
52-Week Range
$74.75–142.00
Bid/Ask
$124.20 / $124.38
Market Cap
$49.24 Bil
Volume/Avg
8.6 Mil / 3.2 Mil

Key Statistics

Price/Earnings (Normalized)
83.16
Price/Sales
15.43
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
1.34%

Company Profile

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Growth
Total Number of Employees
9,600
Website
https://www.dexcom.com

Competitors

Valuation

View More
Metric
DXCM
MDT
ABT
Price/Earnings (Normalized)
 83.1614.7424.07
Price/Book Value
 24.332.054.80
Price/Sales
 15.433.294.63
Price/Cash Flow
 70.5414.5219.20
Price/Earnings
DXCM
MDT
ABT

Financial Strength

Metric
DXCM
MDT
ABT
Quick Ratio
 2.391.461.16
Current Ratio
 2.842.301.64
Interest Coverage
 29.348.8610.86
Quick Ratio
DXCM
MDT
ABT

Profitability

Metric
DXCM
MDT
ABT
Return on Assets (Normalized)
 10.63%7.75%10.63%
Return on Equity (Normalized)
 30.83%13.75%20.87%
Return on Invested Capital (Normalized)
 11.67%9.87%14.81%
Return on Assets
DXCM
MDT
ABT
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Medical Devices Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesFqbhldmMrxyrbk$185.4 Bil
SYK
Stryker CorpPyjtvqqvgXmrz$127.7 Bil
BSX
Boston Scientific CorpYlbbqzsCfpvr$107.6 Bil
MDT
Medtronic PLCGtzbjmcdQbrhhgm$105.9 Bil
EW
Edwards Lifesciences CorpWxskfvzcxCvlwkh$52.0 Bil
ZBH
Zimmer Biomet Holdings IncTzjxnfdybFzym$24.6 Bil
ALGN
Align Technology IncVzcmtspFfmwczh$23.4 Bil
PHG
Koninklijke Philips NV ADRDphwwzwclFvgxzxv$18.7 Bil
PODD
Insulet CorpPpcttxhxFrcvnj$11.6 Bil

Sponsor Center